ASH 2020 | Blinatumomab therapy following hyper-CVAD in B-cell ALL
Nicholas Short, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a Phase II study (NCT02877303) of hyper-CVAD and sequential blinatumomab therapy in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (ALL). Combination chemotherapy achieves high complete remission rates but many patients relapse. Since blinatumomab, a CD19-targeting bispecific T-cell engager, is highly effective in relapsed/refractory ALL, its earlier integration into the treatment regimen was trialled with the goal of generating more durable responses and decreasing the need for chemotherapy. The trial results so far suggest deep and durable responses and enrollment is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consulting fees: Takeda Oncology, AstraZeneca
Research funding: Takeda Oncology, Astellas Pharma Inc.
Honoraria: Amgen
